Fecha de publicación: -- Fuente: Biotechblog Drug patent strategy lives and dies by the calendar. And yet, most companies still treat key NCE milestones like theyre optional.
In a world where one wrong assumption can shift exclusivity by monthsor yearsthis is the most expensive habit in pharma: f...
Source